Therefore, L, Q, and K, the active ingredients of SAIN, may play an important role in improving or treating NSCLC (LUAD and LUSC) after acting on the targets EGFR, MET, MMP1, and MMP3. Here, MET is linked to non-small cell lung carcinoma.